A novel aurone RNA CAG binder inhibits the huntingtin RNA-protein interaction

Area of Science:

• Biochemistry
• Neuroscience
• Molecular Biology

Background:

• Huntington's disease (HD) is a fatal neurodegenerative disorder.
• The disease is caused by expanded CAG repeats in the huntingtin gene (HTT).
• Mutant RNA CAG repeat expansions lead to aberrant RNA-binding protein recruitment, driving neurodegeneration.

Purpose of the Study:

• To identify novel therapeutic strategies for Huntington's disease.
• To find molecules that can interfere with the pathological interactions of mutant HTT RNA.
• To explore the potential of aurones as ligands for disease-related RNA sequences.

Main Methods:

• In vitro screening for RNA-binding compounds.
• Utilizing an aurone scaffold to design potential binders.
• Assessing the binding affinity of identified compounds to mutant HTT mRNA and its interaction with MID1 protein.

Main Results:

• A novel aurone-based compound was identified as a binder.
• This compound effectively reduced the binding of mutant HTT mRNA to the MID1 protein in vitro.
• Aurones demonstrate potential as ligands for targeting disease-related RNA.

Conclusions:

• Aurones represent a promising new class of molecules for therapeutic development in Huntington's disease.
• The identified aurone binder offers a novel approach to disrupt pathogenic RNA-protein interactions.
• Further research into aurone derivatives could lead to effective treatments for HD.